Compare
ImmunityBio, Inc. vs Agenus Inc vs Atara Biotherapeutics, Inc. vs Sutro Biopharma, Inc.
| Latest fiscal year | ImmunityBio, Inc. IBRX | Agenus Inc AGEN | Atara Biotherapeutics, Inc. ATRA | Sutro Biopharma, Inc. STRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $113.29M | $114.20M | $120.77M | $102.48M |
| Revenue growth (YoY) | +668.3% | +10.4% | -6.3% | +65.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -226.0% | -17.7% | 29.7% | -154.5% |
| Net margin | -310.2% | -2.7% | 27.1% | -186.5% |
| Net income | -$351.40M | -$3.08M | $32.69M | -$191.09M |
| EPS (Diluted) | -$0.38 | $0.00 | $2.57 | -$22.49 |
| Operating cash flow | -$304.94M | -$77.19M | -$50.94M | -$177.23M |
| Free cash flow | -$308.78M | -$77.20M | -$50.94M | n/a |
| Cash & equivalents | $88.33M | $3.00M | $8.48M | $58.13M |
| Total assets | $501.90M | $226.80M | $20.23M | $173.83M |
| Total liabilities | $1.00B | n/a | $58.74M | $306.28M |
| Shareholders' equity | -$500.47M | -$271.11M | -$38.50M | -$132.45M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 1.01B | 35.32M | 7.32M | 8.58M |
Revenue, most recent five fiscal years
| Fiscal year | ImmunityBio, Inc. | Agenus Inc | Atara Biotherapeutics, Inc. | Sutro Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $113.29M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $120.77M Ended 2025-12-31 | $102.48M Ended 2025-12-31 |
| 1 year earlier | $14.74M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $128.94M Ended 2024-12-31 | $62.04M Ended 2024-12-31 |
| 2 years earlier | $622.0K Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $8.57M Ended 2023-12-31 | $153.73M Ended 2023-12-31 |
| 3 years earlier | $240.0K Ended 2022-12-31 | $98.02M Ended 2022-12-31 | $63.57M Ended 2022-12-31 | $67.77M Ended 2022-12-31 |
| 4 years earlier | $934.0K Ended 2021-12-31 | $295.67M Ended 2021-12-31 | n/a | $61.88M Ended 2021-12-31 |